MCHP — Microchip Technology Incorporated

The sell-side and the tape are telling different stories as of 2026-09-13. Sell-side is firmly constructive: consensus rating Buy (32 of 46 ratings at buy or strong buy, zero sells), average price target $110.50 and a recent-target average of $99.50, i.e. 34–49% above the $74.20 close. The fundamental news flow supports that — the Aug 6, 2026 FQ1 FY27 print showed continued sequential stabilization, the July 24 Hailo edge-AI acquisition added a structural narrative, and partnerships with Micron (PCIe Gen 6, Aug 4) and Marelli (software-defined vehicle displays, Sep 3) keep the AI/data-center and auto stories alive. But the tape is skeptical: -6.60% over one month, -22.09% over three months, price 0.66% below its 20-day, 5.56% below its 50-day and 4.67% below its 200-day, with RSI at 46.68 (dead neutral). Trailing valuation optics (102.8x TTM P/E, 7.87x TTM P/S) and a high beta (1.736) keep near-term buyers cautious even as the recovery thesis holds.

This is a textbook cyclical inflection, not a blip, and the trajectory has been clean for five quarters. Revenue troughed at $970.5M in the March-2025 quarter, down ~57% from the $2,254.3M September-2023 peak, then grew sequentially every quarter: $1,075.5M (Jun-25, +10.8%), $1,140.4M (Sep-25, +6.0%), $1,186.0M (Dec-25, +4.0%), $1,311.2M (Mar-26, +10.6%), and $1,484.7M (Jun-26, +13.2%) — that latest quarter was +38.1% year over year and the largest sequential jump of the recovery, i.e. accelerating, not decelerating. Gross margin tells the same story: 51.6% at the March-2025 trough, then 53.6% → 55.9% → 59.6% → 61.0% → 63.2% in the June-2026 quarter, a ~1,160bp round trip. Operating margin went from -10.3% (Mar-25, trough, charge-laden) to 3.0% → 8.3% → 12.8% → 16.1% → 22.7% in the June-2026 quarter — four straight quarters of expansion, with the most recent quarter alone adding 662bp sequentially. Diluted EPS followed: -$0.29 → -$0.086 → $0.077 → $0.064 → $0.21 → $0.37; the flat spot in the December-2025 quarter ($34.9M net income versus $41.7M in September-2025 despite higher revenue) looks like below-the-line noise rather than a demand problem, since it immediately reversed. Free cash flow is the cleanest confirmation: $51.6M in the September-2025 quarter versus $497.6M in the June-2026 quarter, with TTM FCF of ~$1.11B and trailing OCF up ~86% year over year. The accruals ratio of -1.96% means reported net income is running below operating cash flow — the conservative, healthy pattern. Balance-sheet repair is also underway: long-term debt cut from $6.75B (Dec-24) to $5.36B (Jun-26), though cash is thin at $272.3M.

Expensive on every trailing metric, reasonable on forward numbers — the classic cyclical-trough optical problem. As of 2026-09-13 at $74.20: TTM P/E 102.8x versus a 5-year average of 79.4x, TTM P/S 7.87x versus a 5-year average of 6.25x (a ~26% premium), P/B 6.24x, EV/EBITDA 27.3x, price/cash 150x, and a dividend yield of 2.45%. PEG of 0.121 is meaningless when the denominator is trough TTM EPS of $0.831. The forward math is far more forgiving: $74.20 against next-FY consensus EPS of $3.641 is ~20.4x, and against consensus revenue of $6.40B it's ~6.3x forward sales for a 60%+ gross-margin franchise. That ~20x forward multiple sits at the low end of MCHP's mid-cycle forward range (~20–26x) and at a discount to mega-cap analog peers, but it is not cheap for a company with 0.83 debt-to-equity and a high beta. The deterministic score's 'Rich vs. its own history' label (15.4) is driven almost entirely by trailing earnings and sales ratios that still embed the March-2025 trough quarter.

As of 2026-09-13, the $74.20 price embeds a lot of recovery but not all of it. It is ~89x trailing EPS but only ~20x next-FY consensus EPS of $3.641 — the market is clearly paying for the earnings that haven't arrived yet, which is the correct way to price a cyclical but also leaves no room for a stall. The 30% gap between the current price and the 52-week high of $105.91, plus a 22% three-month drawdown, says the market is not fully crediting the sell-side's $99.50–$110.50 targets; the bulls are underwriting roughly four more quarters of sequential revenue growth and continued margin expansion toward the mid-20s. The practical read: earnings revisions, not the multiple, will drive the next leg. If FQ2 FY27 (November 2026) shows revenue above ~$1.5B with operating margin continuing up from 22.7%, estimates rise and the stock re-rates without the multiple stretching. If industrial or automotive orders push out, the same stock is expensive on every trailing measure and a retest of the high-$50s/$60s is entirely plausible.

Range-bound and basing, not broken, as of 2026-09-13. RSI(14) of 46.68 is dead neutral — neither oversold nor overbought, so no mean-reversion signal in either direction. Price is 0.66% below its 20-day SMA (~$74.7), 5.56% below its 50-day (~$78.6) and 4.67% below its 200-day (~$77.8); the 50-day is still marginally above the 200-day (~$78.6 vs ~$77.8), so the longer-term structure hasn't rolled over even though price is beneath both. Return profile: +0.04% over one week, -6.60% over one month, -22.09% over three months, +19.79% over six months — a sharp corrective pullback inside a larger recovery, consistent with the +3.66% bounce off $71.58 on the latest session being the first sign of stabilization. Entry-timing implication: no urgency to chase; the stock needs to reclaim the ~$78.6 50-day to confirm the pullback is over, and scaling in on weakness toward the high-$60s is the better risk-adjusted approach than buying strength here.

• Analog/MCU inventory correction is ending — the sector's demand replenishment is the single largest swing factor for MCHP, and the five-quarter sequential revenue ramp suggests it is genuinely underway rather than a head fake.
• AI/data-center capital expenditure boom — MCHP participates indirectly through clock/timing, PCIe Gen 6 storage interface (Micron partnership) and Ethernet bridge content, with management targeting a >$1B annual data-center revenue run rate; this is incremental to, not a substitute for, the core industrial/auto cycle.
• Interest rates and leverage — MCHP carries $5.36B of long-term debt against a beta of 1.736; easing rates help both interest coverage and the multiple, but industrial capital spending remains tightly linked to manufacturing PMI prints.
• Automotive and industrial transitions — software-defined vehicle architectures (e.g. the September 3, 2026 Marelli ASA Motion Link partnership) are a durable secular tailwind, but near-term global auto production and industrial capex remain soft and could delay the recovery by a quarter or two.
• China exposure and trade/export policy — a meaningful share of MCU demand is China-based, making tariffs, export controls and any renewed US-China friction a persistent, hard-to-model swing risk for both revenue and gross margin.

• FQ2 FY27 earnings and forward guidance in early-to-mid November 2026 — the single most important near-term event; watch for revenue above ~$1.5B and operating margin continuing upward from 22.7% toward the mid-20s.
• Closing and integration of the Hailo edge-AI/neural-processing acquisition announced July 24, 2026, including any disclosed synergy targets or revenue contribution.
• Quantification of data-center revenue progress against the >$1B annualized target (timing devices, PCIe Gen 6 storage interfaces with Micron, Ethernet bridges), which is the piece of the story least dependent on the industrial cycle.
• Capital-allocation signals: with ~$497.6M of quarterly free cash flow versus a roughly $250M quarterly dividend, debt reduction, buybacks or a dividend step-up would all be read positively.
• Rate cuts and an industrial PMI inflection, which would reinforce the cyclical recovery and support the high-beta, leveraged balance sheet.

• Leverage and thin cash cushion: $5.36B long-term debt against only $272.3M cash, with the 2.45% dividend absorbing roughly half of the $497.6M June-2026 quarterly free cash flow — little buffer if the recovery stalls or rates stay higher for longer.
• Cyclical double-dip: the recovery is already five quarters old and consensus now assumes continued sequential growth to $6.40B revenue; any industrial or automotive order pushout would hit a stock trading at ~89x trailing earnings with no valuation support.
• Valuation risk on reported numbers: TTM P/E 102.8x, P/S 7.87x (26% above the 5-year average of 6.25x), EV/EBITDA 27.3x and price/cash 150x mean a single guidance miss could compress the multiple sharply.
• Execution and dilution: integration risk on Hailo, plus shareholder approval on August 20, 2026 of a 12-million-share expansion to the equity incentive plan, which is modest but persistent dilution.
• High beta (1.736) plus China/tariff exposure means macro shocks get amplified — the 52-week range of $48.52–$105.91 shows how violent this name's swings can be.

This is a real cyclical recovery, not a value trap: five consecutive quarters of sequential revenue growth, gross margin back to 63.2% from a 51.6% trough, operating margin at 22.7% and rising, and $497.6M of quarterly free cash flow against a $1.11B TTM figure. But at $74.20 as of 2026-09-13, the easy money has arguably already been made — you are paying ~20x next-FY consensus EPS for a leveraged, high-beta franchise whose trailing multiples (102.8x P/E, 7.87x P/S, 27.3x EV/EBITDA) offer zero cushion if the industrial/auto cycle stumbles. The correct posture is patient accumulation on weakness with a two-year horizon rather than a table-pounding buy at this price; the stock is far more attractive near the high-$60s than it is here.

Applied a 23x forward P/E to FMP's next-FY consensus EPS of $3.641 (23 x 3.641 = $83.74), a multiple at the mid-point of MCHP's mid-cycle forward range (~20–26x) and discounted for 0.83 debt-to-equity and a 2.45% dividend that consumes roughly half of quarterly free cash flow. Cross-checked with 19–20x forward EV/EBITDA on ~$2.5–2.7B (consensus revenue of $6.40B at a ~27% operating margin plus ~$0.75–0.95B of D&A) net of ~$5.9B of net debt, which yields ~$80–84; I deliberately did not use the 5-year average P/E of 79.4x or the 102.8x trailing P/E, both of which are trough-distorted and meaningless for a recovering cyclical. The result is ~13% above the 2026-09-13 close of $74.20 and roughly 15% below the recent sell-side target average of $99.50.